MBRX Moleculin Biotech Inc: Earnings per one share for the last 12 months

Moleculin Biotech, Inc. (MBRX) develops small molecules to combat aggressive cancer, leveraging high scientific credibility. R&D activities are accompanied by strict compliance with environmental regulations regarding chemical disposal. The current EPS YoY TTM trajectory, where the parameter equals 98.90, demonstrates the capitalization's resilience to Fed rates, which is critical for the success of anthracycline trials and patient survival rates.
Moleculin Biotech, Inc. - analytical breakdowns and key metrics (MBRX)

This indicator captures the dynamics of net income per share over a trailing twelve-month period, allowing for an assessment of the business's actual capitalization rate relative to previous periods. By analyzing the annual EPS TTM YoY trend, an investor can distinguish random market spikes from systemic growth, which is critically important for Moleculin Biotech, Inc. (MBRX) given its high capital burn rate and the toxicity risks associated with its oncology drug pipeline.